The Real World Study of Apatinib for Gastric Cancer Treatment in Anhui Province
1 other identifier
observational
1,000
1 country
1
Brief Summary
The investigators conduct the real world study to explore the efficacy and safety of Apatinib in gastric cancer .
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Sep 2017
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2017
CompletedFirst Submitted
Initial submission to the registry
October 1, 2017
CompletedFirst Posted
Study publicly available on registry
November 7, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2020
CompletedNovember 7, 2017
September 1, 2017
2 years
October 1, 2017
November 6, 2017
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Progress free survival
Progress free survival is defined as the length of time from random assignment to disease progression or to death resulting from any cause other than the progress.
1 year
Secondary Outcomes (4)
disease control rate
1year
Objective tumor response rate
1year
overall survival
3year
Disease-free survival
1 year
Other Outcomes (2)
Quality of life score
1year
adverse events
1year
Eligibility Criteria
patients of gastric cancer in Anhui province
You may qualify if:
- Male or female patients .
- Confirmed by Pathology or histology of Gastric cancer
- Patients should be voluntary to the trial and provide with signed informed consent
- The researchers believe patients can benefit from the study.
You may not qualify if:
- Patients with a known history of allergic reactions and/or hypersensitivity attributed to apatinib or its accessories
- Pregnant or lactating women
- Patients with Apatinib contraindications
- Patients of doctors considered unsuitable for the trial
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, 230000, China
Related Publications (2)
Peng W, Zhang F, Wang Z, Li D, He Y, Ning Z, Sheng L, Wang J, Xia X, Yu C, Wang Z, Zhao Y, Liang H, Hu B, Sun C, Wang D, Cheng Y, Pan M, Xia L, Guo X, Zhang Y, Hu Z, Li X, Lu L, Zhang J, Qian H, Xie H, Sun G. Large Scale, Multicenter, Prospective Study of Apatinib in Advanced Gastric Cancer: A Real-World Study from China. Cancer Manag Res. 2020 Aug 6;12:6977-6985. doi: 10.2147/CMAR.S249153. eCollection 2020.
PMID: 32821164DERIVEDDu Y, Cao Q, Jiang C, Liang H, Ning Z, Ji C, Wang J, Zhou C, Jiang Z, Yu C, Li L, Zhao Y, Xu Y, Xu T, Hu W, Wang D, Cheng H, Wang G, Zhou J, Wang S, Zhang Y, Hu Z, Li X, Lu D, Zhang J, Xie H, Sun G. Effectiveness and safety of low-dose apatinib in advanced gastric cancer: A real-world study. Cancer Med. 2020 Jul;9(14):5008-5014. doi: 10.1002/cam4.3105. Epub 2020 May 22.
PMID: 32441892DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
China Anhui
The First Affiliated Hospital of Anhui Medical University
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 1, 2017
First Posted
November 7, 2017
Study Start
September 1, 2017
Primary Completion
September 1, 2019
Study Completion
September 1, 2020
Last Updated
November 7, 2017
Record last verified: 2017-09
Data Sharing
- IPD Sharing
- Will share